This would be one less thing to lie awake at night worrying about: In a small study, researchers found that an FDA-approved insomnia drug…
It’s Friday night, your team is playing, and scores are nail-bitingly close. A player intercepts the ball, and bam! A player tackles his opponent…
It can be difficult to tell the difference between early signs of dementia and “normal” aging. And once it’s clear something is off, it…
Sleep seems to play a big — though still mysterious — role in brain health. And mounting research is pointing to a strong link…
In a powerful public statement, former First Lady Rosalynn Carter, 95, and her family earlier today revealed that she is living with dementia. “The…
As Dr. Jeff Chen MD, MBA recalled in a recent talk at the 2023 TED Conference in Vancouver, BC, when he was a medical…
Today, more than 55 million people are living with Alzheimer’s disease globally. In the U.S., one in 10 people over the age of 65,…
Over 30 million people live with Alzheimer’s disease worldwide, making it the most common form of dementia. Two thirds of those diagnoses are women….
The FDA rejected Eli Lilly’s request to expedite the approval process for experimental Alzheimer’s drug donanemab, but the drug’s Phase 3 trial is carrying…
To engage and include relatives living with early Alzheimer’s or dementia in family time, get them talking about their favorite memories from the past….
A second patient has died of brain bleeds — an anti-amyloid side effect — during the clinical trial extension of Eisai’s Alzheimer’s treatment lecanemab…
Why to stop calling them “senior moments” — and how to tell the difference between these typical aging-related memory lapses and dementia. Mild cognitive…
In Phase 3 trials, Roche’s experimental Alzheimer’s drug gantenerumab has failed to meet its objectives for slowing cognitive decline. Most Alzheimer’s treatments on the market…
As the Biden administration rings in National Alzheimer’s Awareness Month, American voters in the midterm elections stand to decide whether prescription drug prices will…
Researchers in Tokyo continue encouraging research on oxytocin as a potential Alzheimer’s drug target. When administered nasally, the hormone appeared to reverse cognitive decline…